335 related articles for article (PubMed ID: 15140637)
1. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
[TBL] [Abstract][Full Text] [Related]
2. Dual PPAR-alpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential.
Madhavan GR; Chakrabarti R; Reddy KA; Rajesh BM; Balraju V; Rao PB; Rajagopalan R; Iqbal J
Bioorg Med Chem; 2006 Jan; 14(2):584-91. PubMed ID: 16198573
[TBL] [Abstract][Full Text] [Related]
3. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
4. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
[TBL] [Abstract][Full Text] [Related]
5. Studies on the euglycemic and hypolipidemic potentials of the novel indole analogue of thiazolidinedione, DRF 2189.
Chakrabarti R; Vikramadithyan RK; Dileepkumar T; Kumar KB; Kumar MP; Misra P; Rao PB; Lohray VB; Lohray BB; Rajagopalan R
Arzneimittelforschung; 1999 Nov; 49(11):905-11. PubMed ID: 10604043
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; Pénicaud L
Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
[TBL] [Abstract][Full Text] [Related]
7. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
[TBL] [Abstract][Full Text] [Related]
8. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
9. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
Huang TH; Peng G; Li GQ; Yamahara J; Roufogalis BD; Li Y
Toxicol Appl Pharmacol; 2006 Feb; 210(3):225-35. PubMed ID: 15975614
[TBL] [Abstract][Full Text] [Related]
10. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
11. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
Hu X; Feng Y; Shen Y; Zhao XF; Yu JH; Yang YS; Leng Y
Acta Pharmacol Sin; 2006 Oct; 27(10):1346-52. PubMed ID: 17007742
[TBL] [Abstract][Full Text] [Related]
12. PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.
Lanne B; Dahllöf B; Lindahl C; Ebefors K; Kanmert I; von Bahr H; Miliotis T; Nyström AC; Arnerup G; Paulsons I; Kerb S; Oakes N
J Proteome Res; 2006 Aug; 5(8):1850-9. PubMed ID: 16889406
[TBL] [Abstract][Full Text] [Related]
13. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
14. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
15. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
El Midaoui A; Wu L; Wang R; de Champlain J
Am J Hypertens; 2006 Apr; 19(4):407-12. PubMed ID: 16580578
[TBL] [Abstract][Full Text] [Related]
17. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
18. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
19. DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
Vikramadithyan RK; Hiriyan J; Suresh J; Gershome C; Babu RK; Misra P; Rajagopalan R; Chakrabarti R
Obes Res; 2003 Feb; 11(2):292-303. PubMed ID: 12582227
[TBL] [Abstract][Full Text] [Related]
20. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
